Affiliation:
1. Translational Research Laboratory Instituto de Medicina Integral Prof. Fernando Figueira (IMIP) Recife Brazil
2. Research Department Hospital de Câncer de Pernambuco Recife Brazil
3. Department of Medicine Postgraduate Program in Translational Medicine, Universidade Federal de São Paulo (UNIFESP) São Paulo Brazil
4. Department of Digestive Surgery Universidade Federal de São Paulo (UNIFESP) São Paulo Brazil
Abstract
AbstractBackgroundCo‐inhibitor and co‐stimulator mediators trigger actions that result in immunological homeostasis and are being evaluated as potential therapeutic targets in gastric cancer (GC).ObjectiveTo evaluate the soluble levels of sPD‐1, sPD‐L1, sPD‐L2, sTIM‐3, sGal9, sGITR, and sGITRL in GC patients.MethodsThe cross‐sectional study was carried out at the Hospital de Cancer de Pernambuco, Brazil between 2017 and 2018. A total of 74 GC patients and 30 healthy controls were included.ResultsLow levels of sPD1 (p = 0.0179), sPDL2 (p = 0.0003), and sGal9 (p < 0.0001), and higher levels of sPDL1 (p = 0.004), sTIM‐3 (p = 0.0072), sGITR (p = 0.0179), and sGITRL (p = 0.0055) compared to the control group. High sPD‐1, sTIM‐3, and sGal9 levels in stage IV compared I/II and III (p < 0.05). High sPDL1, sGal9, and sGITRL levels in esophagogastric junction compared to body and Pylorus/Antrum groups (p < 0.05). No significant differences were observed in sPD1, sPDL1, sPDL2, sTIM3, sGal9, sGITR, and sGITRL levels between the intestinal, diffuse, and mixed GC groups. Low sGITR levels in GC patients who died within the first 24 months compared to the who survived (p = 0.0332).ConclusionsThere is an association of sPD1, sTIM‐3, and sGal9 with disease progression and sGITR with death, these mediators may be potential prognostic biomarkers in GC.